



Cite this: *RSC Adv.*, 2017, 7, 25640

# ATR-FTIR spectroscopy coupled with multivariate analysis techniques for the identification of DENV-3 in different concentrations in blood and serum: a new approach

Marfran C. D. Santos,<sup>a</sup> Yasmin M. Nascimento,<sup>bc</sup> Josélio M. G. Araújo <sup>bc</sup> and Kássio M. G. Lima <sup>\*a</sup>

In most cases of virus infections the viral load is directly related to the intensity of the disease. Nowadays, the main routine diagnoses for dengue fever are only qualitative, they only inform us if the patient has dengue fever or not. However, it is important to be aware of the patient's viral load so that proper care can be taken. In this study we used attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) coupled with multivariate analysis techniques to identify and discriminate dengue serotype 3 (DENV-3) diluted in different concentrations in serum and blood samples with the purpose of developing a simple, fast and non-destructive methodology for a quantitative analysis of the dengue virus. Techniques such as principal component analysis-linear discriminant analysis (PCA-LDA), successive projection algorithm – linear discriminant analysis (SPA-LDA) and genetic algorithm – linear discriminant analysis (GA-LDA) were applied in this classification problem. Forty samples (40 for serum and 40 for blood) were infected with DENV-3 at different concentrations (ten samples for each concentration) and analyzed by IR spectroscopy. The results showed that the models were successful in classifying the virus, the best results being for blood samples. The results of the multivariate classification were tested based on sensitivity, specificity, positive and negative predictive values, Youden's index and positive and negative likelihood ratios, suggesting that ATR-FTIR spectroscopy coupled with multivariate analysis algorithms is an effective tool in quantifying the dengue virus in providing rapid results, in addition to being non-destructive to the sample.

Received 22nd March 2017  
 Accepted 4th May 2017

DOI: 10.1039/c7ra03361c

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Dengue fever is the most transmitted viral disease in the world<sup>1</sup> and dengue viruses (DENV) 1 to 4 are members of the genus *Flavivirus* of the family *Flaviviridae*. Infection by a serotype leaves the individual immune to subsequent infections by the same serotype throughout their life and immune to another serotype for only a few months.<sup>2,3</sup> Dengue is an infection caused by a virus transmitted by arthropods. It is estimated that currently more than 50 million infections occur annually, of which 500 000 lead to hospitalizations for dengue hemorrhagic fever (DHF), with a mortality rate of more than 5% in some regions.<sup>4</sup>

Clinical complications caused by dengue virus infection may range from mild asymptomatic infection to dengue fever (DF) or more severe manifestations such as dengue hemorrhagic fever and dengue shock syndrome (DSS).<sup>5-7</sup> In most cases, patients do not feel the symptoms or feel an undifferentiated fever with or without redness showing on the body. In the case of DF symptoms, they are usually a high fever, headache, muscle pain (myalgia), joint pain (arthralgia), pain behind the eyes and redness on the body. Patients with DHF and DSS present high fever, bleeding, thrombocytopenia and hemoconcentration as the main symptoms, and may develop other complications such as pleural effusion and gastrointestinal or gingival bleeding.<sup>7,8</sup>

Viral isolation, RNA detection, antigen detection and serological methods for detecting IgM and IgG are among the most widely used methods in laboratory diagnosis and in virological studies,<sup>9,10</sup> but both of these methods have some limitations such as sample handling, requiring samples in the acute phase, and are time-consuming to achieve results, among others. Analyzing diagnostic methods, the most widely used methods in hospitals and diagnostic clinics are serological methods. These methods are qualitative, that is, they only inform if the

<sup>a</sup>Biological Chemistry and Chemometrics, Institute of Chemistry, Federal University of Rio Grande do Norte, Natal 59072-970, Brazil. E-mail: [kassiolima@gmail.com](mailto:kassiolima@gmail.com); Tel: +55 84 3342 2323

<sup>b</sup>Laboratory of Molecular Biology for Infectious Diseases and Cancer, Department of Microbiology and Parasitology, Federal University of Rio Grande do Norte, Natal 59072-970, Brazil

<sup>c</sup>Laboratory of Virology, Institute of Tropical Medicine, Federal University of Rio Grande do Norte, Natal 59072-970, Brazil



patient is or is not infected. However, knowledge of the patient's viral load is of great importance, since in most cases the viral load is directly related to the intensity and stage of the disease. The more viruses circulating, the more severe the disease is normally, and the greater the care taken. Finally, identification of the viral load, for some viruses (HIV mainly), can be used to evaluate if the treatment is being effective (if the viral load decreases, it is assumed that the treatment is working). In the case of dengue, rapid determination of viral load can be used as a parameter to decide whether or not treatment is needed. With this in mind, a quantitative test that is inexpensive, quick and requires no sample handling is necessary so that clinical treatment can be started as quickly as possible.

Spectroscopy studies the behavior of samples against their interaction with radiation. Spectroscopic techniques are known to provide fast and reliable results and its use in biological studies has been defined by biospectroscopy.<sup>11</sup> Several studies have been carried out using spectroscopy for virology purposes, such as detection and quantification of the poliovirus using FTIR spectroscopy,<sup>12</sup> detection of hepatitis C virus infection using NMR spectroscopy,<sup>13</sup> and diagnosis of HIV-1 infection using near-infrared spectroscopy,<sup>14</sup> among others, showing promising results regarding the technique's ability to identify the presence of the virus.

The mid-infrared region comprises the 400 to 4000  $\text{cm}^{-1}$  of the electromagnetic spectrum. This radiation is absorbed by molecules present in biological samples. The 900 to 1800  $\text{cm}^{-1}$  range is known as the biomolecule fingerprint region, because spectral bands present referral to lipids ( $\sim 1750 \text{ cm}^{-1}$ ), carbohydrates ( $\sim 1155 \text{ cm}^{-1}$ ), proteins (amide I,  $\sim 1650 \text{ cm}^{-1}$ , amide II,  $\sim 1550 \text{ cm}^{-1}$ , amide III,  $\sim 1260 \text{ cm}^{-1}$ ) and DNA/RNA ( $\sim 1225 \text{ cm}^{-1}$ ,  $1080 \text{ cm}^{-1}$ ).<sup>15,16</sup> In general, attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR) can be used for collecting spectra in this range.<sup>15</sup>

When interrogating different biological samples with FTIR, the generated spectra have a lot of information which can make interpreting difficult; therefore, it is convenient to use algorithms that aid and facilitate spectral interpretation. In this study we used principal component analysis (PCA – it reduces data dimensionality, making use of the components that explain data variability),<sup>16</sup> successive projection algorithm and genetic algorithm (SPA and GA – they reduce the size of the data, selecting the variables that discriminate classes)<sup>17,18</sup> and linear discriminant analysis (LDA – it provides a maximum separation of classes through the ratio of the variance between classes and within the classes) as chemometric algorithms of multivariate classification for discriminating classes *via* spectral information.

Classification by different concentrations of the dengue virus through ATR-FTIR spectra using the PCA-LDA, SPA-LDA and GA-LDA algorithms has never been studied. This study aims to quantitatively discriminate DENV-3 samples in serum and blood. The results were encouraging and show the potential of the technique to identify and quantify DENV-3, and it may be used in the future as ancillary tools for clinical diagnostics.

## Material and methods

### Subculture of cells

VERO E6 cells (African green monkey kidney cells) biological sample has been used by biomedical laboratories worldwide. It is very common for collaborating research groups to share this cell line. In this study, the VERO E6 cells were kindly provided by the Biotechnology Laboratory of Natural Polymer-Biopol, Department of Biochemistry, Federal University of Rio Grande do Norte (UFRN). VERO E6 cells (African green monkey kidney cells) cultivated at 37 °C in 5%  $\text{CO}_2$  were used in the study. Leibovitz's 15 (L-15) medium of the culture bottle (25  $\text{cm}^3$ ) was discarded and subsequently 5 mL of PBS was poured in to remove cell debris (2 times, then discarding PBS). 1000  $\mu\text{L}$  of trypsin was added and then incubated for 5 minutes at 37 °C. Then it was observed in a microscope to check if total monolayer displacement occurred. Upon observing total displacement, 10 mL of 10% L-15 medium was added to the bottle along with homogenates and 5 mL was transferred to a sterile bottle.

### Replication of dengue virus

Aliquots from cultivated DENV-3 were kindly provided by the staff from the Laboratory of Molecular Biology for Infectious Diseases and Cancer (LADIC/UFRN). Isolated DENV-3 was inoculated into VERO E6 cells with the purpose of promoting viral replication. Next, 100  $\mu\text{L}$  viral sample was used in a 25  $\text{cm}^3$  bottle of cells. It was incubated for 1 hour at 37 °C, being homogenized every 15 minutes. Then medium was added with 2% fetal bovine serum (FBS) in order to provide nutrients for the cell. Finally, it was incubated again at 37 °C where it remained for 7 days, and was observed daily. Confirmation of viral infection was performed by nested Reverse Transcriptase PCR assay (RT-PCR). After the viral infection was confirmed, the supernatant was transferred to a falcon and centrifuged for 5 minutes at 1000 turns per minute. Lastly, 20% fetal bovine serum was added to the virus isolate and stored at  $-70 \text{ }^\circ\text{C}$ . The titer of DENV-3 was determined by plaque assay at  $1 \times 10^4 \text{ PFU mL}^{-1}$ .

### RNA extraction and nested Reverse Transcriptase PCR assay (RT-PCR)

Viral RNA for the nested RT-PCR assay was extracted by using QIAamp® Viral RNA Mini kit, Qiagen (Catalog number 52906), in accordance with the manufacturer. The nested RT-PCR protocol for DENV detection and typing was performed as previously described by Lanciotti *et al.* (1992).

### Sample preparation

For IR measurement, healthy human serum and blood samples were infected with DENV-3 in conical-bottomed microtubes at four dilutions ( $1 \times 10^3$ ,  $1 \times 10^2$ , 1 and 0.1  $\text{PFU mL}^{-1}$  for serum, and  $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and 0.1  $\text{PFU mL}^{-1}$  for blood). All experiments were performed in compliance with the guideline "Biomedical research ethics review method involving people" (Brazil), and approved by the medical ethics committee at



Federal University of Rio Grande do Norte/Brazil (protocol number # 51057015.5.0000.5537), informed consents were obtained from human participants of this study. The data set consisted of 40 samples (40 for serum and 40 for blood) divided into ten for each dilution. Another 10 non-infected serum and blood samples were used as a control.

### ATR-FTIR spectroscopy

Spectra acquisition was performed within 1 hour of sample contamination. ATR-FTIR spectra were performed using a BRUKER model FTIR VERTEX 70 equipped with ATR accessory. The spectra were obtained in the range of 400 to 4000  $\text{cm}^{-1}$ , with a resolution of 4  $\text{cm}^{-1}$ , with 16 scans and a measurement time of 13 seconds per spectrum. The ambient temperature was 22 °C. Air was used as background in obtaining the spectra of samples contaminated with DENV-3. Soon after each acquisition of the background, 2  $\mu\text{L}$  of each sample was added to the ATR crystal, making sure that no air bubbles were trapped. At each acquisition, a small piece of aluminum foil was placed on the sample, following the studies of Cui *et al.* (2016) where it has been observed that this is an appropriate substrate for ATR-FTIR analyzes of various biological specimens because it does not interfere with the spectra, does not sacrifice important biochemical fingerprint information of the sample and is inexpensive.<sup>19</sup> After the acquisitions, the crystal was then cleaned with alcohol (70% v/v) and dried using paper towel. In order to make sure the ATR crystal was clean, a spectrum was

collected using the latest background collected for reference. BRUKER OPUS software was used to convert the spectra to absorbance.

### Chemometric methods and software

Principal Component Analysis (PCA) is a multivariate statistical method that seeks to determine a smaller set of variables from the linear combination of the original variables which summarize the original system, thus reducing the dimensionality and complexity of the data. A reduction of variables is performed in which the original spectral matrix  $X$  is decomposed as the product of the matrices scores and loadings,<sup>20</sup> as shown in eqn (1):

$$X = TP^T + E \quad (1)$$

where:  $X$  is the  $I \times J$  data matrix ( $I$  is the number of objects and  $J$  is the number of variables);  $T$  is the  $I \times A$  matrix of score vectors ( $A$  is the number of calculated components);  $P$  is the  $J \times A$  matrix of loadings vectors (the superscript T indicates the transpose of the matrix  $P$ ); and  $E$  is the  $I \times J$  residual matrix.

Successive Projection Algorithm (SPA) is a variable selection method (in this case, the variables are the wavenumbers) that uses simple operations in a vector space to minimize variable collinearity. SPA is a direct selection method, meaning it starts with 1 variable and then incorporates another variable in each interaction until it reaches a number of more discriminant  $N$  variables.<sup>20</sup>



Fig. 1 Raw spectra for each original class: (a) DENV-3 in serum ( $1 \times 10^3$ ,  $1 \times 10^2$ , 1 and 0, 1 PFU  $\text{mL}^{-1}$ ); (b) DENV-3 in blood ( $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and 0, 1 PFU  $\text{mL}^{-1}$ ).



Genetic algorithm (GA) was another technique used for variable selection. This algorithm makes use of techniques based on biological genetics and evolution. A population is created with  $n$  subsets, where each subset is composed by a random combination of variables (wavenumbers). Each subset is formed by  $m$  (the total number of variables that can be chosen), 1's (variables selected by the model) and 0's (unselected variables). Therefore, in genetic terms, each variable represents a gene, and a set of variables represents a chromosome. For example, for a selection problem with 10 variables, a chromosome could be 1001010110, where variables 1, 4, 6, 8 and 9 would be the variables selected for the model, and variables 2, 3, 5, 7 and 10 would be the variables to be optimized.<sup>21</sup> In this study for the GA routine, the number of individuals (population) for each generation was 24, with the number of generations equal to 12. The genetic operator mutation and crossover were held constant at 10 and 60%, respectively. GA was repeated three times and the best result was used. In this study, in order to select the best optimal number of variables for SPA and GA we used a cost function calculated in the validation set,<sup>22</sup> as shown in eqn (2):

$$G = \frac{1}{N_V} \sum_{n=1}^{N_V} g_n \quad (2)$$

in eqn (2),  $g_n$  is defined as:

$$g_n = \frac{r^2(x_n, m_{l(n)})}{\min_{l(m) \neq l(n)} r^2(x_n, m_{l(m)})} \quad (3)$$

where  $l(n)$  is the index of the true class for the  $n^{\text{th}}$  validation object  $x_n$ .

Linear Discriminant Analysis (LDA) was another technique employed. It is a supervised technique that is based on the discriminant process developed by Fisher in 1936. LDA maximizes the ratio between the variance between classes and intraclass variation in any particular data set, thus ensuring maximum separability. LDA is efficient when combined with dimensionality reduction techniques (such as PCA, SPA and GA).

The results of the multivariate classification for PCA-LDA, SPA-LDA and GA-LDA were tested based on: sensitivity (confidence in obtaining a positive result for a truly positive sample):

$$\text{sens}(\%) = \frac{\text{TP}}{\text{TP} + \text{FN}} \times 100 \quad (4)$$

specificity (confidence in obtaining a negative result for a sample actually negative values):

$$\text{spec}(\%) = \frac{\text{TN}}{\text{TN} + \text{FP}} \times 100 \quad (5)$$




Fig. 2 Pre-processed spectra (cut between 900 and 1800  $\text{cm}^{-1}$ , baseline correction and smoothing) of: (a) DENV-3 in serum ( $1 \times 10^3$ ,  $1 \times 10^2$ , 1 and 0.1 PFU  $\text{mL}^{-1}$ ); (b) DENV-3 in blood ( $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and 0.1 PFU  $\text{mL}^{-1}$ ).



positive predictive values (PPV; measures the proportion of correctly assigned positive examples, and their value ranges from 0 to 1):

$$PPV = \frac{TP}{TP + FP} \quad (6)$$

negative predictive values (NPV; measures the proportion of correctly assigned negative examples and their value ranges from 0 to 1):

$$NPV = \frac{TN}{TN + FN} \quad (7)$$

Youden's index (YOU; assesses the ability of the classifier to avoid failures):

$$YOU = \text{sens} - (1 - \text{spec}) \quad (8)$$

positive likelihood ratios (LR(+); represents the ratio between the probability of predicting a sample as positive when it is truly

positive and the probability of predicting one as positive when it is not positive):

$$LR(+) = \frac{\text{sens}}{1 - \text{spec}} \quad (9)$$

negative likelihood ratios (LR(-); represents the ratio between the probability of predicting a sample as negative when it is positive and the probability of predicting a sample as negative when it is truly negative):

$$LR(-) = \frac{1 - \text{sens}}{\text{spec}} \quad (10)$$

where TP is defined as true positive, FP is false positive, TN is true negative and FN is false negative.

MATLAB R2012b software (Math-works, Natick, USA) was used for data import, pre-treatment, and construction of the chemometric classification models. The raw spectra were pre-processed with cuts between 900 and 1800  $\text{cm}^{-1}$  (235




Fig. 3 DF1  $\times$  DF2 discriminant function values calculated with 4 PC's for: (a) DENV-3 in serum ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 1$  and  $\bullet 0.1$  PFU  $\text{mL}^{-1}$ ); (b) DENV-3 in blood ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 10$  and  $\bullet 0.1$  PFU  $\text{mL}^{-1}$ ).

Table 1 Variables selected by SPA-LDA to obtain the classification of different concentrations of DENV-3 in serum and blood

Chemometric analysis	Wavenumber selected ( $\text{cm}^{-1}$ )
SPA-LDA for DENV-3 in serum	908, 943, 989, 1041, 1080, 1124, 1144, 1194, 1302, 1315, 1360, 1441, 1477, 1500, 1541, 1578, 1632, 1695, 1724, 1801
SPA-LDA for DENV-3 in blood	918, 989, 1049, 1076, 1105, 1151, 1227, 1304, 1317, 1356, 1414, 1489, 1524, 1564, 1618, 1653, 1682, 1718, 1801





Fig. 4 Graph of the variables selected by SPA-LDA, marked in the average spectrum of: (a) DENV-3 in serum and (b) DENV-3 in blood.




Fig. 5 DF1  $\times$  DF2 discriminant function values calculated with the variables selected by SPA-LDA for: (a) DENV-3 in serum ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 10$  and  $\bullet 0,1$  PFU mL $^{-1}$ ); (b) DENV-3 in blood ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 10$  and  $\bullet 0.1$  PFU mL $^{-1}$ ).





wavenumbers at  $4\text{ cm}^{-1}$  spectral resolution), baseline-corrected and Savitzky–Golay smoothing (window 15 points). The samples were divided into three sets for the PCA-LDA, SPA-LDA and GA-LDA models (60% for training, 20% for validation and 20% for prediction) using the classic Kennard–Stone uniform sampling algorithm.<sup>23</sup> The KS algorithm was applied separately for each class to maximize the Euclidean minimum distances between selected and unselected samples.

Due to the great similarity between the spectra of the different classes, it is necessary to use algorithms (PCA-LDA, SPA-LDA and GA-LDA, in this case) that mathematically find spectral information capable of discriminating one class from another. The models were applied to classify the serum and blood samples by the concentration of DENV-3 present, and finally their performances were compared. The results are discussed below.

## Results and discussion

In Fig. 1a and b we can see the raw spectra of infected serum ( $1 \times 10^3$ ,  $1 \times 10^2$ , 1 and  $0.1\text{ PFU mL}^{-1}$ ) and infected blood samples ( $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and  $0.1\text{ PFU mL}^{-1}$ ), respectively. These spectra were subjected to pre-processing (cut between 900 and  $1800\text{ cm}^{-1}$ , baseline correction and smoothing) and the results can be seen in Fig. 2a and b. As can be seen, the spectra are very similar, being impossible the visual differentiation between them.

### PCA-LDA

Fig. 3a and b show the plot of the Fisher scores in a two-dimensional space resulting from principal component analysis-linear discriminant analysis (PCA-LDA) for the infected serum and blood samples, respectively. Each point represents a spectrum of a sample. As can be seen, Fisher scores do not show good segregation between classes. For this study the PCA-LD was performed using 4 principal components (4 PC's, 94% of

Table 2 Variables selected by GA-LDA to obtain the classification of different concentrations of DENV-3 in serum and blood

Chemometric analysis	Wavenumber selected ( $\text{cm}^{-1}$ )
GA-LDA for DENV-3 in serum	905, 926, 949, 984, 1047, 1055, 1176, 1196, 1277, 1311, 1321, 1396, 1448, 1554, 1603, 1753, 1761
GA-LDA for DENV-3 in blood	986, 1053, 1065, 1225, 1337, 1352, 1529, 1541, 1666, 1686, 1689




Fig. 6 Graph of the variables selected by GA-LDA, marked in the average spectrum of: (a) DENV-3 in serum and (b) DENV-3 in blood.



variance explained for serum samples and 95% for blood samples).

### SPA-LDA and GA-LDA

Then, SPA-LDA and GA-LDA were applied to select an optimal number of variables through the minimum cost of the  $G$  function. Fisher scores were obtained for both models, with a better segregation of the classes in relation to the PCA-LDA models.

In the case of infected serum samples the SPA-LDA selected 20 wave numbers, while for the case of infected blood samples the SPA-LDA selected 19 wave numbers (Table 1). The selected wave numbers are like biological markers, selected by the models as the variables that most discriminate one class from another. Fig. 4a and b show the graphs of the selected variables by SPA-LDA for serum and blood DENV-3 samples, respectively. Using these selected variables, the Fisher scores were calculated (shown in Fig. 5). As can be seen, Fisher scores for SPA-LDA show a better segregation of classes than those calculated for PCA-LDA, being visually better separated for dengue-3 samples in blood than in serum.

In analyzing the wavenumbers selected by SPA-LDA for the contaminated serum samples, we observed that the main biological changes of interest that discriminate the different concentrations are related to amide II of proteins ( $\approx 1500 \text{ cm}^{-1}$ )

and RNA ( $\approx 1080 \text{ cm}^{-1}$ ) vibrations. When examining the wavenumbers selected by SPA-LDA for infected blood samples, the main changes are related to carbohydrate ( $\approx 1151 \text{ cm}^{-1}$ ), protein structures (amide I,  $\approx 1653 \text{ cm}^{-1}$ , amide III,  $\approx 1317 \text{ cm}^{-1}$ ), and RNA ( $\approx 1227 \text{ cm}^{-1}$ ,  $\approx 1076 \text{ cm}^{-1}$ ) vibrations.

In the case of the GA-LDA, 17 wavenumbers were selected for the infected serum samples and 11 wavenumbers for the infected blood samples (Table 2). The graph of the selected variables can be seen in Fig. 6. As can be seen in Fig. 7, Fisher scores showed good visual segregation between classes, mainly in the case of infected blood samples (as in the case of SPA-LDA).

Among the 17 wavenumbers selected by GA-LDA that best discriminate infected serum samples, we can highlight changes related to protein structures (amide III,  $\approx 1311 \text{ cm}^{-1}$ , amide II,  $\approx 1554 \text{ cm}^{-1}$ ),  $\text{COO}^-$  symmetric stretch in fatty acids ( $\approx 1396 \text{ cm}^{-1}$ ) and lipid ( $\approx 1753 \text{ cm}^{-1}$ ) vibrations. Among the 11 wavenumbers selected by GA-LDA in the case of infected blood samples, those that appear to be of major biological interest are related to RNA ( $\approx 1238 \text{ cm}^{-1}$ ), protein structures (amide III,  $\approx 1329 \text{ cm}^{-1}$ , amide I,  $\approx 1661 \text{ cm}^{-1}$ ) and lipid ( $\approx 1743 \text{ cm}^{-1}$ ) vibrations. The changes associated with RNA make sense, since even within a single serotype there are minimal differences found between the RNA of one viral particle and another.




Fig. 7 DF1  $\times$  DF2 discriminant function values calculated with the variables selected by GA-LDA for: (a) DENV-3 in serum ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 10$  and  $\bullet 0.1$  PFU mL $^{-1}$ ); (b) DENV-3 in blood ( $\bullet 1 \times 10^3$ ,  $\bullet 1 \times 10^2$ ,  $\bullet 10$  and  $\bullet 0.1$  PFU mL $^{-1}$ ).





**Table 3** Measurements of the performance of PCA-LDA, SPA-LDA and GA-LDA in classifying different concentrations of DENV-3 in serum by FTIR spectroscopy

DENV-3 in serum			
Stage performance features	PCA-LDA	SPA-LDA	GA-LDA
<b>1 × 10<sup>3</sup> PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	50.0
Specificity (%)	100.0	100.0	100.0
Positive predictive values (PPV)	100.0	100.0	100.0
Negative predictive values (NPV)	100.0	100.0	66.6
Youden index (YOU)	100.0	100.0	50.0
Positive likelihood ratios (LR+)	0.0	0.0	0.0
Negative likelihood ratios (LR-)	0.0	0.0	0.5
<b>1 × 10<sup>2</sup> PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	100.0
Specificity (%)	100.0	100.0	50.0
Positive predictive values (PPV)	100.0	100.0	66.6
Negative predictive values (NPV)	100.0	100.0	100.0
Youden index (YOU)	100.0	100.0	50.0
Positive likelihood ratios (LR+)	0.0	0.0	2.0
Negative likelihood ratios (LR-)	0.0	0.0	0.0
<b>1 PFU mL<sup>-1</sup></b>			
Sensitivity (%)	0.0	50.0	50.0
Specificity (%)	0.0	50.0	100.0
Positive predictive values (PPV)	0.0	50.0	100.0
Negative predictive values (NPV)	0.05	0.0	66.6
Youden index (YOU)	100.0	0.0	50.0
Positive likelihood ratios (LR+)	0.0	1.0	0.0
Negative likelihood ratios (LR-)	0.0	1.0	0.5
<b>0.1 PFU mL<sup>-1</sup></b>			
Sensitivity (%)	50.0	100.0	0.0
Specificity (%)	50.0	100.0	100.0
Positive predictive values (PPV)	50.0	100.0	0.0
Negative predictive values (NPV)	50.0	100.0	50.0
Youden index (YOU)	0.0	100.0	0.0
Positive likelihood ratios (LR+)	1.0	0.0	0.0
Negative likelihood ratios (LR-)	1.0	0.0	1.0

**Table 4** Measurements of the performance of PCA-LDA, SPA-LDA and GA-LDA in classifying different concentrations of DENV-3 in blood by FTIR spectroscopy

DENV-3 in blood			
Stage performance features	PCA-LDA	SPA-LDA	GA-LDA
<b>1 × 10<sup>3</sup> PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	100.0
Specificity (%)	100.0	100.0	100.0
Positive predictive values (PPV)	100.0	100.0	100.0
Negative predictive values (NPV)	100.0	100.0	100.0
Youden index (YOU)	100.0	100.0	100.0
Positive likelihood ratios (LR+)	0.0	0.0	0.0
Negative likelihood ratios (LR-)	0.0	0.0	0.0
<b>1 × 10<sup>2</sup> PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	100.0
Specificity (%)	100.0	100.0	100.0
Positive predictive values (PPV)	100.0	100.0	100.0
Negative predictive values (NPV)	100.0	100.0	100.0
Youden index (YOU)	100.0	100.0	100.0
Positive likelihood ratios (LR+)	0.0	0.0	0.0
Negative likelihood ratios (LR-)	0.0	0.0	0.0
<b>10 PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	100.0
Specificity (%)	100.0	100.0	100.0
Positive predictive values (PPV)	100.0	100.0	100.0
Negative predictive values (NPV)	100.0	100.0	100.0
Youden index (YOU)	100.0	100.0	100.0
Positive likelihood ratios (LR+)	0.0	0.0	0.0
Negative likelihood ratios (LR-)	0.0	0.0	0.0
<b>0.1 PFU mL<sup>-1</sup></b>			
Sensitivity (%)	100.0	100.0	100.0
Specificity (%)	100.0	100.0	100.0
Positive predictive values (PPV)	100.0	100.0	100.0
Negative predictive values (NPV)	100.0	100.0	100.0
Youden index (YOU)	100.0	100.0	100.0
Positive likelihood ratios (LR+)	0.0	0.0	0.0
Negative likelihood ratios (LR-)	0.0	0.0	0.0

The good segregations shown for SPA-LDA and for GA-LDA give us an indication that these chemometric models will provide good results for figures of merit [sensitivity, specificity, PPV, NPV, YOU, LR(+) and LR(-)].

The performances of the method were evaluated through validation measures. Tables 3 and 4 presents the performance measures for PCA-LDA, SPA-LDA and GA-LDA for serum and blood samples with different concentrations of DENV-3, respectively. As can be seen, the models made some errors for the serum samples, however they obtained an excellent classification performance for the blood samples (in this case, PCA-LDA, SPA-LDA and GA-LDA obtained 100% sensitivity and specificity), demonstrating that ATR-FTIR spectroscopy together with classification techniques has the potential to quantitatively discriminate the dengue virus (in this case DENV-3) in serum and blood, and may, in the near future, assist in the more detailed diagnosis and correct treatment of patients.

## Conclusion

The spectra acquisition of each infectious agent can be identified to avoid cross-reactions in cases of co-infections or comorbidities. Serum and blood-based vibrational spectroscopy has been applied in studies with various diseases, but it has never been used in the quantitative classification of dengue virus (determination of dengue viral load). The importance of this determination is related to the fact that the viral load is associated with disease time, and, in most cases, is directly related to the severity of the disease. A patient with a high viral load needs a more urgent treatment. Thus, a rapid and sensitive technique for quantitative determination of the virus may assist in the correct treatment of patients or inform those patients who do not need treatment. The results of this study suggest that IR spectroscopy with multivariate classification techniques (PCA-LDA, SPA-LDA and GA-LDA, in this case) can be applied in this clinical perspective. Principal component-based dimensional reduction techniques (PCA) and variable selection (SPA



and GA) combined with LDA were performed in an attempt to extract information from the ATR-FTIR spectra that best differentiate the DENV-3 concentrations. In comparing the DENV-3 samples in serum and DENV-3 in blood, the implemented classification models obtained better results for blood samples, with 100% sensitivity and specificity values for PCA-LDA, SPA-LDA and GA-LDA. Although the results have been encouraging, it is necessary to carry out studies with a larger number of samples for greater reliability. However, this study shows that further research is worth exploring in this perspective and suggests that in the near future we will be able to rely on portable spectroscopic instruments that emit specific radiation and simultaneous multivariate analyzes in the clinical and virological study environments.

## Acknowledgements

Marfran C. D. Santos would like to thank CAPES for its financial support and the PPGQ-UFRN for its scientific support. This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq (grant No. 305962/2014-0 and 400328/2014-3).

## References

- 1 *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control*: New Edition, World Health Organization, Geneva, 2009.
- 2 D. J. Gubler, *Comp. Immunol. Microbiol. Infect. Dis.*, 2004, **27**, 319–330.
- 3 I. Kurane, *Comp. Immunol. Microbiol. Infect. Dis.*, 2007, **30**, 329–340.
- 4 M. G. Guzman, S. B. Halstead, H. Artsob, P. Buchy, J. Farrar, D. J. Gubler, E. Hunsperger, A. Kroeger, H. S. Margolis, E. Martínez, M. B. Nathan, J. L. Pelegriño, C. Simmons, S. Yoksan and R. W. Peeling, *Nat. Rev. Microbiol.*, 2010, **8**, S7–S16.
- 5 S. B. Halstead and S. N. Cohen, *Microbiol. Mol. Biol. Rev.*, 2015, **79**, 281–291.
- 6 S. R. Sudulagunta, M. B. Sodalagunta, M. Sepehrar, S. K. B. Raja, A. S. Nataraju, M. Kumbhat, D. Sathyanarayana, S. Gummadi and H. Kumar, *Oxford Med. Case Reports*, 2016, vol. 11, pp. 269–272.
- 7 M. G. Guzman, M. Alvarez and S. B. Halstead, *Arch. Virol.*, 2013, **158**, 1445–1459.
- 8 R. W. Peeling, H. Artsob, J. L. Pelegriño, P. Buchy, M. J. Cardoso, S. Devi, D. A. Enria, J. Farrar, D. J. Gubler, M. G. Guzman, S. B. Halstead, E. Hunsperger, S. Kliks, H. S. Margolis, C. M. Nathanson, V. C. Nguyen, N. Rizzo, S. Vázquez and S. Yoksan, *Nat. Rev. Microbiol.*, 2010, **8**, S30–S37.
- 9 M. G. Guzmán and G. Kourí, *Int. J. Infect. Dis.*, 2004, **8**, 69–80.
- 10 P. Heraud and M. J. Tobin, *Stem Cell Res.*, 2009, **3**, 12–14.
- 11 F. Lee-Montiel, K. Reynolds and M. Riley, *J. Biol. Eng.*, 2011, **5**, 1–13.
- 12 M. M. G. Godoy, E. P. A. Lopes, R. O. Silva, F. Hallwass, L. C. A. Koury, I. M. Moura, S. M. C. Gonçalves and A. M. Simas, *J. Viral Hepatitis*, 2010, **17**, 854–858.
- 13 A. Sakudo, Y. Suganuma, R. Sakima and K. Ikuta, *Clin. Chim. Acta*, 2012, **413**, 467–472.
- 14 J. G. Kelly, J. Trevisan, A. D. Scott, P. L. Carmichael, H. M. Pollock, P. L. Martin-Hirsch and F. L. Martin, *J. Proteome Res.*, 2011, **10**, 1437–1448.
- 15 B. E. Obinaju and F. L. Martin, *Environ. Pollut.*, 2013, **183**, 46–53.
- 16 G. Theophilou, K. M. G. Lima, P. L. Martin-Hirsch, H. F. Stringfellow and F. L. Martin, *Analyst*, 2016, **141**, 585–594.
- 17 A. S. Marques, M. C. N. de Melo, T. A. Cidral and K. M. G. de Lima, *J. Microbiol. Methods*, 2013, **98**, 26–30.
- 18 A. S. Marques, E. P. Moraes, M. A. A. Júnior, A. D. Moura, V. F. A. Neto, R. M. Neto and K. M. G. Lima, *Talanta*, 2015, **134**, 126–131.
- 19 L. Cui, H. J. Butler, P. L. Martin-hirsch and F. L. Martin, *Anal. Methods*, 2016, 1–7.
- 20 A. S. Marques, M. C. N. Melo, T. A. Cidral and K. M. G. Lima, *J. Microbiol. Methods*, 2014, **98**, 26–30.
- 21 R. M. Jarvis and R. Goodacre, *Bioinformatics*, 2005, **21**, 860–868.
- 22 K. M. G. Lima, K. Gajjar, G. Valasoulis, M. Nasioutziki, M. Kyrgiou, P. Karakitsos, E. Paraskevidis, P. L. Martin Hirsch and F. L. Martin, *Anal. Methods*, 2014, **6**, 9643–9652.
- 23 R. W. Kennard and L. A. Stone, *Technometrics*, 1969, **11**, 137–148.

